Table 3.
Site of infections and isolated pathogens in the 128 targeted antimicrobial therapies underwent ECPA program
| Site of infectionsa | |
| Pneumonia | 50 (38.2%) |
| Bloodstream infection | 34 (26.0%) |
| Complicated intra-abdominal infection | 29 (22.1%) |
| Complicated urinary tract infection | 9 (6.9%) |
| Bone and joint infection | 4 (3.1%) |
| Necrotizing soft tissue infection | 2 (1.5%) |
| Meningitis | 2 (1.5%) |
| Catheter-related bloodstream infection | 1 (0.7%) |
| Isolated pathogensb | |
| Gram-positive (9) | |
| Staphylococcus aureus | 7 (5.1%) |
| Enterococcus faecium | 2 (1.4%) |
| Gram-negative (115) | |
| Pseudomonas aeruginosa | 31 (22.6%) |
| Escherichia coli | 24 (17.5%) |
| Klebsiella pneumoniae | 22 (16.1%) |
| Proteus mirabilis | 7 (5.1%) |
| Enterobacter cloacae complex | 7 (5.1%) |
| Klebsiella aerogenes | 6 (4.3%) |
| Serratia marcescens | 4 (2.9%) |
| Klebsiella oxytoca | 2 (1.4%) |
| Klebsiella variicola | 2 (1.4%) |
| Morganella morganii | 2 (1.4%) |
| Acinetobacter baumannii | 2 (1.4%) |
| Proteus vulgaris | 1 (0.7%) |
| Citrobacter koseri | 1 (0.7%) |
| Hafnia alvei | 1 (0.7%) |
| Pantoea spp | 1 (0.7%) |
| Acinetobacter pittii | 1 (0.7%) |
| Stenotrophomonas maltophilia | 1 (0.7%) |
| Anaerobes (1) | |
| Bacteroides faecis | 1 (0.7%) |
| Atypical (4) | |
| Legionella pneumophila | 4 (2.9%) |
| Fungi (8) | |
| Candida albicans | 5 (3.7%) |
| Candida glabrata | 1 (0.7%) |
| Aspergillus fumigatus | 1 (0.7%) |
| Aspergillus terreus | 1 (0.7%) |
| Virus | |
| CMV reactivation | 1 (0.7%) |
aOverall, 131 different site of infections were identified for the 128 targeted antimicrobial therapies
bOverall, 137 different pathogens were identified for the 128 targeted antimicrobial therapies
CMV cytomegalovirus
Data are presented as n (%)